564 reports of this reaction
2.6% of all BRINZOLAMIDE reports
#2 most reported adverse reaction
DYSPNOEA is the #2 most commonly reported adverse reaction for BRINZOLAMIDE, manufactured by Sandoz Inc. There are 564 FDA adverse event reports linking BRINZOLAMIDE to DYSPNOEA. This represents approximately 2.6% of all 21,426 adverse event reports for this drug.
Patients taking BRINZOLAMIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for BRINZOLAMIDE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for BRINZOLAMIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 564 FDA reports for BRINZOLAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.6% of all adverse event reports for BRINZOLAMIDE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking BRINZOLAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.